Multiple retrospective analyses also reported that the development of irAEs was associated with better survival outcomes in patients with NSCLC treated with PD-(L)-1 inhibitors (17, 33), and patients with greater toxicity to ICIs could attain better tumor-killing effects (18). Here, CD274 is linked to neoplasm.